Prelude Capital Management’s Spark Therapeutics, Inc. Common Stock ONCE Stock Holding History

Prelude Capital Management’s Portfolio ONCE Stock Details ONCE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-239,791	Closed	-$23.3M	–	2418
2019 Q3	$23.3M	Buy	239,791 +5,541	+2%	+$555K	1.05%	8
2019 Q2	$24M	Buy	234,250 +128,681	+122%	+$13.9M	1.18%	13
2019 Q1	$12M	Buy	+105,569	New	+$7.76M	0.68%	19
2018 Q4	–	Sell	-103	Closed	-$6K	–	2355
2018 Q3	$6K	Buy	+103	New	+$7.04K	﹤0.01%	1625
2017 Q4	–	Sell	-2,220	Closed	-$198K	–	1879
2017 Q3	$198K	Sell	2,220 -3,167	-59%	-$240K	0.02%	657
2017 Q2	$322K	Buy	+5,387	New	+$301K	0.03%	439
2015 Q4	–	Sell	-3,678	Closed	-$153K	–	1796
2015 Q3	$153K	Hold	3,678	–	–	0.02%	702
2015 Q2	$222K	Buy	+3,678	New	+$243K	0.03%	550

Prelude Capital Management's ONCE Position: Q4 2019 in Review

Prelude Capital Management sold out of Spark Therapeutics, Inc. Common Stock (ONCE) in Q4 2019, closing a stake of 239,791 shares — an estimated $23.3M sold.

Prelude Capital Management first reported a position in ONCE in Q2 2015 and held it in 8 quarters. The position peaked at $24M in Q2 2019. 0 funds tracked by Wall St. Rank hold ONCE as of Q4 2019.

Prelude Capital Management reported no remaining Spark Therapeutics, Inc. Common Stock position as of Q4 2019 after selling out during the quarter.
Prelude Capital Management sold 239,791 Spark Therapeutics, Inc. Common Stock shares in Q4 2019, an estimated $23.3M.
Prelude Capital Management first reported a position in Spark Therapeutics, Inc. Common Stock in Q2 2015 and held it in 8 quarters.
Prelude Capital Management's Spark Therapeutics, Inc. Common Stock position peaked at $24M in Q2 2019.
0 funds tracked by Wall St. Rank held Spark Therapeutics, Inc. Common Stock as of Q4 2019.

Based on Prelude Capital Management's 13F filing for Q4 2019, filed 14 Feb 2020.